Literature DB >> 19438479

Advances in understanding the bleeding diathesis in factor V deficiency.

Connie Duckers1, Paolo Simioni, Jan Rosing, Elisabetta Castoldi.   

Abstract

Coagulation factor V (FV), present in plasma and platelets, is an indispensable clotting factor, as demonstrated by the uniform lethality of FV knock-out mice. Surprisingly, however, severe FV deficiency is rarely fatal in humans. In fact, although several cases of life-threatening intracranial haemorrhage have been reported in FV-deficient newborns, many patients with undetectable FV levels experience only mild to moderate bleeding and do not require routine prophylaxis. While the reasons for this variable phenotypic expression are largely unknown, several observations from different laboratories indicate platelets as crucial players in FV deficiency. Moreover, we have recently shown that plasma levels of tissue factor pathway inhibitor are considerably reduced in FV-deficient plasma, which results in enhanced thrombin generation especially at very low FV levels (<2%). The present review discusses and integrates these findings in the context of the biology of FV and the clinical features of FV deficiency.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19438479     DOI: 10.1111/j.1365-2141.2009.07708.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  14 in total

1.  Platelets and platelet-derived factor Va confer hemostatic competence in complete factor V deficiency.

Authors:  Beth A Bouchard; John Chapin; Kathleen E Brummel-Ziedins; Peter Durda; Nigel S Key; Paula B Tracy
Journal:  Blood       Date:  2015-04-20       Impact factor: 22.113

2.  Acquired factor V deficiency in a patient without evidence of a classical inhibitor.

Authors:  I R Sosa; P Ellery; A Mast; A T Neff; D Gailani
Journal:  Haemophilia       Date:  2013-10-14       Impact factor: 4.287

3.  A bipartite autoinhibitory region within the B-domain suppresses function in factor V.

Authors:  Mettine H A Bos; Rodney M Camire
Journal:  J Biol Chem       Date:  2012-06-15       Impact factor: 5.157

4.  Blood coagulation factors V and VIII: Molecular Mechanisms of Procofactor Activation.

Authors:  Mettine H A Bos; Rodney M Camire
Journal:  J Coagul Disord       Date:  2010-07-01

5.  Prothrombin activation on the activated platelet surface optimizes expression of procoagulant activity.

Authors:  Jeremy P Wood; Jay R Silveira; Nicole M Maille; Laura M Haynes; Paula B Tracy
Journal:  Blood       Date:  2010-12-03       Impact factor: 22.113

6.  Hip Replacement Surgery in 14-Year-Old Girl with Factor V Deficiency: Haemostatic Treatment and Thromboprophylaxis.

Authors:  María Eva Mingot-Castellano; Josefina Pérez-Núñez; Lourdes Baeza-Montañez
Journal:  Case Rep Hematol       Date:  2016-10-30

7.  Phenotype Report on Patients with Congenital Factor V Deficiency in Southern Iran: Recent Ten Years' Experience.

Authors:  Mohammad Mostafa Safarpour; Sezaneh Haghpanah; Aidin Meshksar; Mehran Karimi
Journal:  Turk J Haematol       Date:  2017-03-08       Impact factor: 1.831

8.  Anti-Factor V inhibitor in patients with autoimmune diseases: case report and literature review.

Authors:  Shinsaku Imashuku; Takeshi Hasegawa; Kagekatsu Kubo; Masaki Nakato; Midori Shima
Journal:  Int Med Case Rep J       Date:  2011-04-20

9.  Acquired factor V inhibitor in a patient with mantle cell lymphoma presenting with hematuria followed by thrombosis: a case report.

Authors:  Naif I Aljohani; John H Matthews
Journal:  Int Med Case Rep J       Date:  2014-02-24

10.  Factor V Deficiency in Korean Patients: Clinical and Laboratory Features, Treatment, and Outcome.

Authors:  Young Hoon Park; Joo Han Lim; Hyeon Gyu Yi; Moon Hee Lee; Chul Soo Kim
Journal:  J Korean Med Sci       Date:  2016-01-25       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.